DataMeds AI is the former Wellgistics Health listing, not the retired TRxADE Health marketplace that once used this ticker. The live debate is whether a cash-starved wholesale pharmacy roll-up can be recast as a health-data and consumer-app platform before Nasdaq equity rules push it off the Capital Market. Gerald Commissiong, the Fortitude Advisors partner who also runs Tollo Health, joined as interim co-chief executive alongside a term sheet that would leave existing public holders a thin residual while folding Datavault licenses, Tollo products, and biometric patents into the same register.
Management is selling a sequential recovery story. Mid-year sales did rise versus the first quarter, but only after liquidity constraints gutted the wholesale book versus last year. Cash ended mid-year near $2.5 million after discounted convertible notes replaced earlier paper. The equity deficit was still about $20 million, and the mid-year notes state substantial doubt about continuing as a going concern. A May reverse split cured the bid-price notice. The equity-standard clock still runs into October. The July name change and ticker swap do not repair that arithmetic.
September added two real events. A Florida and Delaware fight over the original Wellgistics membership purchase was settled for a modest cash outlay and a share retirement, with the company anticipating a large liability extinguishment. Days later the company bought Helomics, a Pittsburgh cancer-diagnostics lab, from Axe Compute for stock and a note and took in matching cash with the lab. Those moves can help the equity account. They do not, by themselves, prove that Health Lives Here, the NFL Alumni Health launch, or the Datavault close produce a durable operating business. The question the next several weeks resolve is whether equity is evidenced above the Nasdaq floor without handing the register to the term-sheet parties.